NEW YORK, June 24 (GenomeWeb News) - Iconix Pharmaceuticals will provide its chemogenomic profiling technology to Icos, the Mountain View, Calif.-based company said today.
Under the agreement, Icos will use Iconix's chemogenomics platform to study preclinical drug responses and to discover biomarkers to predict drug efficacy and side effects.
Iconix will use its Drug Signature collection of predictive biomarkers, derived from its DrugMatrix chemogenomics reference database.